AddLife (ALIF B) Stock Overview
Provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
ALIF B Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.676.1% undervalued intrinsic discount
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeAddLife AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 145.70 |
| 52 Week High | SEK 208.40 |
| 52 Week Low | SEK 130.20 |
| Beta | 1.57 |
| 1 Month Change | -5.51% |
| 3 Month Change | -0.88% |
| 1 Year Change | -23.48% |
| 3 Year Change | 7.77% |
| 5 Year Change | -28.65% |
| Change since IPO | 429.82% |
Recent News & Updates
Analysis Article • May 01
Earnings Miss: AddLife AB (publ) Missed EPS By 10% And Analysts Are Revising Their Forecasts
The analysts might have been a bit too bullish on AddLife AB (publ) ( STO:ALIF B ), given that the company fell short...
Narrative Update • Apr 26
ALIF B: Higher Dividend Visibility And Premium P/E Support Future Upside
Analysts have revised their price target on AddLife to SEK 190.0 from SEK 187.5, citing updated assumptions regarding fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.5000 per share, with an ex-date on May 7, 2026, a record date on May 8, 2026, and payment scheduled for May 13, 2026 (Key Developments).Recent updates
Analysis Article • May 01
Earnings Miss: AddLife AB (publ) Missed EPS By 10% And Analysts Are Revising Their Forecasts
The analysts might have been a bit too bullish on AddLife AB (publ) ( STO:ALIF B ), given that the company fell short...Narrative Update • Apr 26
ALIF B: Higher Dividend Visibility And Premium P/E Support Future Upside
Analysts have revised their price target on AddLife to SEK 190.0 from SEK 187.5, citing updated assumptions regarding fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.5000 per share, with an ex-date on May 7, 2026, a record date on May 8, 2026, and payment scheduled for May 13, 2026 (Key Developments).Narrative Update • Apr 09
ALIF B: Higher Margins And Dividend Outlook Will Support Future Upside
Analysts have maintained their SEK 187.50 price target on AddLife, with updated assumptions around discount rate, revenue growth, profit margin and future P/E that now reflect a slightly different balance of risk, earnings potential and valuation multiples. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.50 per share, with ex date on May 7, 2026, record date on May 8, 2026, and payment on May 13, 2026 (Key Developments).Narrative Update • Mar 25
ALIF B: Higher Margin Outlook And Dividend Policy Will Support Future Upside
Analysts have trimmed their price target for AddLife from SEK191.50 to SEK187.50, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E levels. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.5000 per share, with an ex date on May 7, 2026, a record date on May 8, 2026, and a payment date on May 13, 2026 (Key Developments).Analysis Article • Feb 12
Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings
AddLife AB (publ)'s ( STO:ALIF B ) stock was strong after they recently reported robust earnings. We did some analysis...Analysis Article • Feb 10
AddLife (STO:ALIF B) Is Increasing Its Dividend To SEK1.50
AddLife AB (publ) ( STO:ALIF B ) will increase its dividend from last year's comparable payment on the 13th of May to...Analysis Article • Feb 07
AddLife AB (publ) Just Beat EPS By 31%: Here's What Analysts Think Will Happen Next
Shareholders of AddLife AB (publ) ( STO:ALIF B ) will be pleased this week, given that the stock price is up 11% to...Narrative Update • Jan 23
ALIF B: Higher P/E Assumptions Will Support Future Upside Potential
Analysts have trimmed their price target for AddLife from SEK 208.50 to SEK 191.50, citing updated assumptions around discount rates, revenue growth, margins and future P/E multiples. Valuation Changes Fair Value: Reduced from SEK 208.50 to SEK 191.50, reflecting a lower central estimate for the share.Narrative Update • Jan 07
ALIF B: Stable Margins And Refined Discount Rate Will Support Future Upside Potential
Analysts have kept their fair value estimate for AddLife steady at SEK 208.50, with small tweaks to inputs like the discount rate and assumed future P/E reflecting fine tuning of their valuation approach, rather than a fundamental shift in their view of the company. Valuation Changes Fair Value Estimate unchanged at SEK 208.50 per share, indicating no revision to the overall target level.Narrative Update • Dec 24
ALIF B Stable Margins And Discount Rate Will Support Future Upside Potential
Analysts have slightly reduced their price target on AddLife by SEK 5 to SEK 208.50, citing a modestly higher discount rate, somewhat softer long term revenue growth assumptions, and a marginally lower profit margin outlook, partly offset by a small increase in expected future valuation multiples. Valuation Changes The fair value estimate has fallen slightly from SEK 213.50 to SEK 208.50.Analysis Article • Dec 10
Why We're Not Concerned About AddLife AB (publ)'s (STO:ALIF B) Share Price
When close to half the companies in Sweden have price-to-earnings ratios (or "P/E's") below 21x, you may consider...Narrative Update • Dec 10
ALIF B: Stable Discount Outlook Will Support Future Share Price Upside
Analysts have modestly reaffirmed their outlook on AddLife, keeping the price target steady at SEK 213.50 as minor tweaks to the discount rate and long term assumptions left the valuation framework essentially unchanged. Valuation Changes Fair Value Estimate: Unchanged at SEK 213.50 per share, reflecting a stable overall valuation framework.Analysis Article • Nov 26
Is AddLife AB (publ) (STO:ALIF B) Potentially Undervalued?
While AddLife AB (publ) ( STO:ALIF B ) might not have the largest market cap around , it saw a double-digit share price...Narrative Update • Nov 25
ALIF B: Stable Financial Metrics Will Support Future Upward Momentum
Analysts have maintained their price target for AddLife at SEK 213.50, citing ongoing stable forecasts for the company's key financial metrics and reaffirming their confidence in its market position. Valuation Changes Consensus Analyst Price Target remains unchanged at SEK 213.50.Narrative Update • Nov 09
ALIF B: Fair Value Strength Will Support Positive Momentum Moving Forward
Narrative Update on AddLife Price Target Analysts have maintained their fair value estimate for AddLife at SEK 213.50. This decision is based on minimal changes to key projections and the market outlook.Narrative Update • Oct 26
Optimized Product Portfolio And Acquisitions Will Deliver Future Value
Narrative Update on AddLife: Analyst Price Target Revision Analysts have raised AddLife's fair value estimate from SEK 200 to SEK 213.5, citing incremental improvements in growth and profitability forecasts. Valuation Changes The consensus analyst price target has increased from SEK 200 to SEK 213.5. The discount rate has risen slightly from 5.70% to 5.75%.Analysis Article • Oct 13
AddLife (STO:ALIF B) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Sep 20
Optimized Product Portfolio And Acquisitions Will Deliver Future Value
Despite a slight decrease in consensus revenue growth forecasts, AddLife’s fair value estimate was marginally raised, with the analyst price target increasing from SEK196.50 to SEK200.00. Valuation Changes Summary of Valuation Changes for AddLife The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from SEK196.50 to SEK200.00.Analysis Article • Aug 06
Shareholders Should Be Pleased With AddLife AB (publ)'s (STO:ALIF B) Price
When close to half the companies in Sweden have price-to-earnings ratios (or "P/E's") below 23x, you may consider...Analysis Article • Jul 18
The AddLife AB (publ) (STO:ALIF B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
AddLife AB (publ) ( STO:ALIF B ) shareholders are probably feeling a little disappointed, since its shares fell 6.1% to...Analysis Article • Jul 15
When Should You Buy AddLife AB (publ) (STO:ALIF B)?
AddLife AB (publ) ( STO:ALIF B ), is not the largest company out there, but it led the OM gainers with a relatively...Analysis Article • May 03
After Leaping 26% AddLife AB (publ) (STO:ALIF B) Shares Are Not Flying Under The Radar
The AddLife AB (publ) ( STO:ALIF B ) share price has done very well over the last month, posting an excellent gain of...Analysis Article • Apr 30
AddLife AB (publ) Just Beat EPS By 8.9%: Here's What Analysts Think Will Happen Next
It's been a pretty great week for AddLife AB (publ) ( STO:ALIF B ) shareholders, with its shares surging 14% to kr174...
New Narrative • Mar 18
Adoption Of AI And Robotics Is Expected To Drive Future Success In Medtech
Continued efficiency initiatives and product optimization are expected to improve profitability and net margins by focusing on high-margin products.Analysis Article • Mar 09
AddLife AB (publ) (STO:ALIF B) Shares Could Be 29% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, AddLife fair value estimate is kr221 AddLife is estimated to...Analysis Article • Feb 08
AddLife AB (publ) (STO:ALIF B) Stock Catapults 31% Though Its Price And Business Still Lag The Industry
AddLife AB (publ) ( STO:ALIF B ) shareholders would be excited to see that the share price has had a great month...Analysis Article • Feb 06
Should You Think About Buying AddLife AB (publ) (STO:ALIF B) Now?
While AddLife AB (publ) ( STO:ALIF B ) might not have the largest market cap around , it received a lot of attention...Analysis Article • Jan 08
AddLife (STO:ALIF B) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Dec 05
There Is A Reason AddLife AB (publ)'s (STO:ALIF B) Price Is Undemanding
You may think that with a price-to-sales (or "P/S") ratio of 1.7x AddLife AB (publ) ( STO:ALIF B ) is a stock worth...Analysis Article • Oct 02
Does AddLife (STO:ALIF B) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jul 26
AddLife AB (publ) (STO:ALIF B) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, AddLife AB (publ) ( STO:ALIF B ) shares have been powering on, with a gain of 26% in the...Analysis Article • Jul 22
AddLife's (STO:ALIF B) Weak Earnings May Only Reveal A Part Of The Whole Picture
AddLife AB (publ)'s ( STO:ALIF B ) stock showed strength, with investors undeterred by its weak earnings report...Analysis Article • Jul 18
Earnings Update: Here's Why Analysts Just Lifted Their AddLife AB (publ) (STO:ALIF B) Price Target To kr155
Shareholders of AddLife AB (publ) ( STO:ALIF B ) will be pleased this week, given that the stock price is up 15% to...Analysis Article • May 29
Revenues Working Against AddLife AB (publ)'s (STO:ALIF B) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 1.4x AddLife AB (publ) ( STO:ALIF B ) is a stock worth...Analysis Article • Apr 22
Are Investors Undervaluing AddLife AB (publ) (STO:ALIF B) By 42%?
Key Insights The projected fair value for AddLife is kr169 based on 2 Stage Free Cash Flow to Equity AddLife is...Analysis Article • Apr 06
Is It Time To Consider Buying AddLife AB (publ) (STO:ALIF B)?
AddLife AB (publ) ( STO:ALIF B ), is not the largest company out there, but it saw a double-digit share price rise of...Analysis Article • Feb 07
AddLife AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
AddLife AB (publ) ( STO:ALIF B ) shareholders are probably feeling a little disappointed, since its shares fell 6.3% to...Analysis Article • Dec 19
AddLife AB (publ)'s (STO:ALIF B) 28% Share Price Surge Not Quite Adding Up
AddLife AB (publ) ( STO:ALIF B ) shares have continued their recent momentum with a 28% gain in the last month alone...Shareholder Returns
| ALIF B | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 2.1% | 2.3% | 0.8% |
| 1Y | -23.5% | -18.2% | 12.3% |
Return vs Industry: ALIF B underperformed the Swedish Life Sciences industry which returned -18.2% over the past year.
Return vs Market: ALIF B underperformed the Swedish Market which returned 12.3% over the past year.
Price Volatility
| ALIF B volatility | |
|---|---|
| ALIF B Average Weekly Movement | 4.9% |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.7% |
Stable Share Price: ALIF B has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: ALIF B's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1906 | 2,295 | Fredrik Dalborg | www.add.life |
AddLife AB (publ), together with its subsidiaries, provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory analysis.
AddLife AB (publ) Fundamentals Summary
| ALIF B fundamental statistics | |
|---|---|
| Market cap | SEK 17.76b |
| Earnings (TTM) | SEK 568.00m |
| Revenue (TTM) | SEK 10.39b |
31.3x
P/E Ratio1.7x
P/S RatioIs ALIF B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALIF B income statement (TTM) | |
|---|---|
| Revenue | SEK 10.39b |
| Cost of Revenue | SEK 6.41b |
| Gross Profit | SEK 3.98b |
| Other Expenses | SEK 3.41b |
| Earnings | SEK 568.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 16, 2026
| Earnings per share (EPS) | 4.66 |
| Gross Margin | 38.29% |
| Net Profit Margin | 5.47% |
| Debt/Equity Ratio | 76.0% |
How did ALIF B perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield32%
Payout RatioDoes ALIF B pay a reliable dividends?
See ALIF B dividend history and benchmarks| AddLife dividend dates | |
|---|---|
| Ex Dividend Date | May 07 2026 |
| Dividend Pay Date | May 13 2026 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 1 day |
Does ALIF B pay a reliable dividends?
See ALIF B dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 11:17 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AddLife AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Karl Norén | Danske Bank |
| Robert Redin | DNB Carnegie |
| Gustav Berneblad | Nordea Markets |